Diabetes-related antibody-testing is a valuable screening tool for identifying monogenic diabetes - a survey from the worldwide SWEET registry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10448586" target="_blank" >RIV/00064203:_____/22:10448586 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/22:10448586
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Ths~_bbYUC" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Ths~_bbYUC</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.diabres.2022.110110" target="_blank" >10.1016/j.diabres.2022.110110</a>
Alternative languages
Result language
angličtina
Original language name
Diabetes-related antibody-testing is a valuable screening tool for identifying monogenic diabetes - a survey from the worldwide SWEET registry
Original language description
AIMS: To evaluate access to screening tools for monogenic diabetes in paediatric diabetes centres across the world and its impact on diagnosis and clinical outcomes of children and youth with genetic forms of diabetes. METHODS: 79 centres from the SWEET diabetes registry including 53,207 children with diabetes participated in a survey on accessibility and use of diabetes related antibodies, c-peptide and genetic testing. RESULTS: 73, 63 and 62 participating centres had access to c-peptide, antibody and genetic testing, respectively. Access to antibody testing was associated with higher proportion of patients with rare forms of diabetes identified with monogenic diabetes (54% versus 17%, p=0.01), lower average whole clinic HbA1c (7.7[Q1,Q2: 7.3-8.0]%/61[56-64]mmol/mol versus 9.2[8.6-10.0]%/77[70-86]mmol/mol, p<0.001) and younger age at onset (8.3 [7.3-8.8] versus 9.7 [8.6-12.7] years p<0.001). Additional access to c-peptide or genetic testing was not related to differences in age at onset or HbA1c outcome. CONCLUSIONS: Clinical suspicion and antibody testing are related to identification of different types of diabetes. Implementing access to comprehensive antibody screening may provide important information for selecting individuals for further genetic evaluation. In addition, worse overall clinical outcomes in centers with limited diagnostic capabilities indicate they may also need support for individualized diabetes management.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diabetes Research and Clinical Practice
ISSN
0168-8227
e-ISSN
1872-8227
Volume of the periodical
192
Issue of the periodical within the volume
October
Country of publishing house
IE - IRELAND
Number of pages
6
Pages from-to
110110
UT code for WoS article
000875619800004
EID of the result in the Scopus database
2-s2.0-85140030177